Phase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation-positive advanced non-small cell lung cancer (Oscillate).

Livingstone, Ann

Phase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation-positive advanced non-small cell lung cancer (Oscillate).

journal contribution

posted on 2024-06-02, 15:11 authored by Ann LivingstoneAnn Livingstone

Phase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation-positive advanced non-small cell lung cancer (Oscillate).

History

Journal

Asia Pacific Journal of Clinical Oncology

Volume

14

Pagination

199-200

Location

London, Eng.

Publisher DOI

https://doi.org/10.1111/ajco.13089

ISSN

1743-7555

Language

eng

Publication classification

E3.1 Extract of paper

Title of proceedings

Asia Pacific Journal of Clinical Oncology

Issue

S7

Publisher

Wiley

Usage metrics

Keywords

Uncategorised value

Phase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation-positive advanced non-small cell lung cancer (Oscillate).

History

Journal

Volume

Pagination

Location

Publisher DOI

ISSN

Language

Publication classification

Title of proceedings

Issue

Publisher

Usage metrics

Categories

Keywords

Licence

Exports